Black Diamond Therapeutics (BDTX) Gains from Investment Securities: 2019-2021
Historic Gains from Investment Securities for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$105,000.
- Black Diamond Therapeutics' Gains from Investment Securities fell 152.50% to -$105,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $110,000, marking a year-over-year decrease of 98.70%. This contributed to the annual value of $249,000 for FY2024, which is N/A change from last year.
- Latest data reveals that Black Diamond Therapeutics reported Gains from Investment Securities of -$105,000 as of Q4 2021, which was up 98.16% from -$5.7 million recorded in Q3 2021.
- Black Diamond Therapeutics' Gains from Investment Securities' 5-year high stood at $8.3 million during Q3 2020, with a 5-year trough of -$5.7 million in Q3 2021.
- For the 3-year period, Black Diamond Therapeutics' Gains from Investment Securities averaged around $766,818, with its median value being $16,000 (2019).
- As far as peak fluctuations go, Black Diamond Therapeutics' Gains from Investment Securities surged by 82,430.00% in 2020, and later crashed by 169.09% in 2021.
- Black Diamond Therapeutics' Gains from Investment Securities (Quarterly) stood at $26,000 in 2019, then surged by 669.23% to $200,000 in 2020, then tumbled by 152.50% to -$105,000 in 2021.
- Its last three reported values are -$105,000 in Q4 2021, -$5.7 million for Q3 2021, and $5.7 million during Q1 2021.